The Medical Journal of Australia ISSN: 0025-729X 1 April 2013 198 6 327-330 ©The Medical Journal of Australia 2013 www.mja.com.au Research tage at diagnosis is critical in determining the probability of survival with colorectal cancer (CRC). In randomised controlled trials, population screening using faecal occult blood tests (FOBT) results in earlier stage at diagnosis for screendetected cancers, 1 and reduced mortality from colorectal malignancy compared with controls. [2] [3] [4] Evaluations of cancer prevention programs with mortality as an end point take many years to complete. However, we know that early stage at diagnosis is linked to better prognosis and reduced mortality from CRC, so stage at diagnosis can serve as a surrogate marker for population mortality, and provides an early signal of program benefit.
After a pilot study in 2003, a faecal immunochemical test (FIT)-based National Bowel Cancer Screening Program (NBCSP) has been progressively rolled out across Australia. Participants in the program receive a free two-sample FIT kit by mail from a central register, collect samples and return them for testing. Results are mailed to participants and their nominated primary care practitioner (PCP). The PCP arranges follow-up of people with positive FIT results.
There is mandatory reporting of CRC in Australia, and the South Australian Cancer Registry (SACR) holds up-to-date records of CRC diagnoses in South Australia, including tumour stage. Thus the data held by the SACR and the NBCSP register records provide an opportunity to evaluate the effect of the NBCSP, as implemented in SA, on CRC stage at diagnosis.
Our primary aim was to determine whether CRCs diagnosed in people who had been invited to the NBCSP were diagnosed at an earlier stage than CRCs diagnosed in people not invited to the program. Our secondary aim was to determine whether downstaging was evident in the subpopulations that participated or that had positive test results in the screening program. 
Methods

Patients
Results
We identified 3481 eligible patients with CRC reported to the SACR. Of these, 221 were allocated to the invited cohort. Staging data were available for 87.0% of patients: no data were available for 6.6%, and a further 6.4% had insufficient data to determine ACPS stage. The invited cohort differed significantly from all other patients in age, SES and remoteness (Box 1).
CRC stage according to invitation to the NBCSP
The stage profiles of the invited cohort compared to the rest of the study population (where stage was known) are shown in Box 2. The difference in stage profiles was highly significant ( 2 = 39.5; P < 0.001; Box 3). In the invited group, the percentage of stage A cancers was 34.8%, versus 19.2% in all other patients (P < 0.001). Similarly, the percentage of stage D cancers was 5.4% in the invited group versus 12.4% in all other patients (P = 0.002).
There was a further shift towards earlier stage at diagnosis when the participant group was compared with all other patients ( 2 = 47.7; P < 0.001). In the participant group, the proportion with stage A was almost double that of all other patients (38.8% versus 19.3%; P < 0.001), while the percentage with stage D was 3.0% versus 12.4% in all other patients (P < 0.001). This trend continued when the positive subgroup stage profile was compared with that of all other patients ( 2 = 47.4; P < 0.001). Of those in the participant group, 151/165 (91.5%) returned a positive FIT result through the NBCSP. The percentage with stage A was twice that of all other patients (39.7% compared with 19.3%; P < 0.001), while the percentage with stage D was 2.6% compared with 12.4% in all other patients (P < 0.001).
Analyses that included or excluded patients with unknown cancer stage had no effect on the statistical significance of any of the findings. Multivariate analyses showed that age and SES were significantly associated with stage at diagnosis (Box 4
Finally, we compared the stage profiles of patients who were invited to the NBCSP but did not participate with the stage profiles of those who were not invited, to determine whether simply receiving an invitation but not participating led to downstaging. These groups did not differ in stage profile ( 2 = 1.07; P = 0.78).
Discussion
In this intention-to-screen analysisbased evaluation of the NBCSP, we found that CRCs diagnosed in people within 1 year of receiving an invitation to participate in the screening program were on average at an earlier stage than CRCs diagnosed in people who did not receive an invitation. There was a large and highly significant increase in stage A lesions and a corresponding decrease in stage D CRC in those invited to the program relative to the rest of the study population, and the shift towards earlier stage progressively increased in participants in the screening test and in those who were recorded as having positive results in the FIT. Thus CRC downstaging was associated with an invitation to the NBCSP, and the strength of the effect increased in groups that excluded non-participants or people who had negative results in the FIT. Downstaging was evident regardless of the inclusion or exclusion of patients with missing or insufficient data to determine staging. In addi- Patients invited to NBCSP All other patients in study population tion, in a multivariate model, the relationship between early stage and screening through the NBCSP persisted when possible confoundersage, SES and remoteness -were taken into account.
Earlier detection of CRC has a major impact on survival. United Kingdom data show 5-year relative survival rates of > 90% for Dukes' stage A cancer and < 7% for Dukes' stage D (Dukes' cancer stages are graded A-D in order of increasing spread and metastases). 6 As randomised controlled trials have shown that CRCs detected through screening are diagnosed at an earlier stage, and screened populations had reduced mortality relative to control populations, [1] [2] [3] [4] it is valid to use downstaging as a surrogate for effect on mortality. The significantly earlier stage profile in patients who participated in the NBCSP should lead to reduced mortality rates in this population.
Although at the moment, only a relatively small proportion of the eligible Australian population is offered screening each year, the proposed gradual expansion of the NBCSP should result in greater reductions in CRC mortality over time, assuming that participation rates remain stable or increase.
Our findings are consistent with an earlier report using a hospital-based database of CRC patients, which showed an earlier stage distribution in people self-reporting that they were diagnosed through the NBCSP, compared with stage in symptomatic patients (ACPS stage I, 40% in those diagnosed through the NBCSP versus 14% in non-participants; and stage IV, 3% in those diagnosed through the NBCSP versus 15% in non-participants). 7 However, that study did not assess all CRCs diagnosed in the entire population. Further, the study was subject to recall bias and did not analyse results on an intention-toscreen basis. Our study included all cases of CRC reported to the SACR over the periods of implementation of the NBCSP pilot program and Phase I trial, and was based on an intentionto-screen analysis, which has allowed us to avoid sampling, temporal and follow-up quality bias.
Our results are also consistent with overseas evaluations of national CRC screening programs, although the methods used vary depending on the health system. The National Bowel Cancer Screening Programme in England reported a shift towards earlier stage disease in participants compared with patients with cancer diagnosed before the screening program. 8 However, it is difficult to determine whether that downstaging represents improvement in practice over time or whether it was a direct result of the program. A decrease in the proportion of more advanced stage tumours for 10 A similar high proportion of stage A cancers was observed in the French pilot study. 11 Unlike the overseas programs, Australia's NBCSP uses the FIT, and this is the first report of downstaging in a mass screening program using this testing method.
It was important to analyse the program in the first instance on an intention-to-screen basis as an impact at such a level demonstrates the value of the public health program and justifies its implementation.
This study has several strengths. Data were obtained from independently held and well managed databases, and individuals were matched across databases, and then de-identified by an independent third party, before analysis by the investigators. Selection bias was minimised, if not removed altogether, as it is unlikely that there was a difference between the proportions of CRCs reported to the SACR among NBCSP participants and the proportion reported among patients diagnosed outside of the program. All CRC diagnoses in the study population resulted from usual followup of patients after testing through the existing public and private primary care systems, and thus there were no systematic biases in the type of followup received by each cohort or in the time from referral to diagnosis. Additionally, stage data were extracted and interpreted by experienced SACR staff from histopathology reports. The cohorts examined had similar low proportions of patients with unknown CRC stage because of missing or insufficient data. Finally, this was a whole-of-population study that compared CRC stage at diagnosis of populations differing only in screening invitation status.
Although this is an observational study and it could be argued that other factors might have influenced stage, it was possible to adjust for a number of potential confounders. A second concern was that it was impossible to directly attribute an invitation to the NBCSP to a specific diagnosis of CRC. However, allocating patients to the invited cohort on the basis of a diagnosis between 14 and 366 days from the date of invitation is reasonable, considering the time taken for the clinical steps to final diagnosis after a positive test result; 14 days would appear to be the shortest time to a diagnosis. This timeline from the date of referral for colonoscopy to a diagnosis of CRC is consistent with results of studies across different health systems. 12 
Conclusion
In the context of a national CRC screening program with normal follow-up care for patients after testing, CRCs were diagnosed at a significantly earlier stage in people who had been invited to the program compared with people not invited to the program. Benefits were even greater in screening participants and those with positive results in the FIT. These results show that CRC screening works in practice and is likely to reduce CRC mortality in Australia.
